Abstract: A press felt assembly for paper production, pulp sheet production, tissue production, or other production requiring surface imprinting. The press felt assembly including a base having a width and a length in a machine direction. The base being formed of a strip formed by generally MD oriented yarns in a planar yarn array that are oriented at a nonparallel angle to the true machine direction. A laminate composite is connected to the base. The laminate composite includes at least a base layer, a first adhesive layer coupled to an upper surface of the base layer, and a plurality of marking yarns coupled to an upper surface of the first adhesive layer. The plurality of marking yarns of the laminate composite are oriented in a generally machine direction.

Abstract: A leak control device includes first and second flow control assembly, each including a flow sensor; a valve assembly with a valve and an actuator; a cable assembly, including a leak detector cable and a leak sensor, such that the leak control device close the valve to stop a flow water through the leak control device, if the leak control device receives a leak indication from the leak sensor or detects a flow anomaly condition in communication with the flow sensor. Also disclosed is a method of installing the leak control device, measuring an actual flow duration of water flow events, measuring an actual flow quantity, measuring an actual daily water usage, and counting an actual number of daily water flow events.

Abstract: Compositions and methods for development of potent siRNA therapeutics for prevention and treatment of Corona Virus (2019-nCoV; COVID-19) infections are provided. The compositions include a pharmaceutical composition comprising siRNA cocktails that target critical viral genes and pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers. Administration methods for prevention and treatment are provided, including airway instillation, subcutaneous injections and nebulizer aerosolization.

Abstract: The techniques of the present disclosure provide a method of inhibiting tumor growth in a tissue of a mammal. The method includes administering to the mammal a therapeutically effective amount of a composition comprising an siRNA molecule that binds to an mRNA that codes for TGF?1 protein, an siRNA molecule that binds to an mRNA that codes for VEGFR2 protein, and a pharmaceutically acceptable carrier comprising a pharmaceutically acceptable polypeptide polymer. The techniques of the present disclosure also provide for additional methods for using this composition.

Abstract: The current invention provides a method of activating fibroblast and myofibroblast apoptosis in a tissue of a mammal, comprising administering to the tissue a therapeutically effective amount of a composition comprising an siRNA molecule that binds to an mRNA that codes for TGFB1 protein in a mammalian cell, an siRNA molecule that binds to an mRNA that codes for COX-2 protein in a mammalian cell, and a pharmaceutically acceptable carrier comprising a pharmaceutically acceptable histidine-lysine polymer. The invention also provides additional methods for using this composition.

Abstract: A seamed press felt formed from a base fabric having a CD width and an MD length with two opposing MD ends that are joined to form a continuous belt. MD oriented yarns form uniform loops at the two opposing MD ends that are interdigitated to define a pintle channel extending across the CD width. CD oriented yarns are connected to the MD oriented yarns, in a woven or non-woven construction. Loop open spaces are located within the loops on each of the two opposing MD ends in a seam region, with the loop open spaces being defined between a last one of the CD yarns at each of the two opposing MD ends and the pintle channel. At least one CD monofilament support yarn is located in the loop open spaces on each of the two opposing MD ends. The at least one CD monofilament support yarn has a diameter that is at least 1.6 times a diameter of the CD oriented yarns. A pintle extends through the pintle channel to form a seam.

Abstract: Compositions and methods are provided for silencing the Sulf2 and/or GPC3 genes in vivo. Potent siRNA sequences are provided that silence regions of the Sulf2 and GPC3 genes that are identical in human, mice and non-human primates. Combinations of siRNAs also are provided that result in additivity or synergy with silencing of Sulf2 and/or GPC3. Silencing SULF2+TGF?1 showed a dramatic effect against cancer growth in vitro and in vivo.

Abstract: The present invention relates to compositions and methods for siRNA therapeutics for prevention and treatment of Middle East Respiratory Syndrome Corona Virus (MERS-CoA) infections. The compositions include a pharmaceutical composition comprising siRNA cocktails that target viral genes and pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers.

Abstract: A seamed press felt formed from a base fabric having a CD width and an MD length with two opposing MD ends that are joined to form a continuous belt. MD oriented yarns form uniform loops at the two opposing MD ends that are interdigitated to define a pintle channel extending across the CD width. CD oriented yarns are connected to the MD oriented yarns, in a woven or non-woven construction. Loop open spaces are located within the loops on each of the two opposing MD ends in a seam region, with the loop open spaces being defined between a last one of the CD yarns at each of the two opposing MD ends and the pintle channel. At least one CD monofilament support yarn is located in the loop open spaces on each of the two opposing MD ends. The at least one CD monofilament support yarn has a diameter that is at least 1.6 times a diameter of the CD oriented yarns. A pintle extends through the pintle channel to form a seam.

Abstract: Compositions and methods for development of potent siRNA therapeutics for prevention and treatment of Corona Virus (2019-nCoV; COVID-19) infections are provided. The compositions include a pharmaceutical composition comprising siRNA cocktails that target critical viral genes and pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers. Administration methods for prevention and treatment are provided, including airway instillation, subcutaneous injections and nebulizer aerosolization.

Abstract: The present invention relates to compositions and methods for siRNA therapeutics for prevention and treatment of Middle East Respiratory Syndrome Corona Virus (MERS-CoV) infections. The compositions include a pharmaceutical composition comprising siRNA cocktails that target viral genes and pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers.

Abstract: The current invention provides a method of activating fibroblast and myofibroblast apoptosis in a tissue of a mammal, comprising administering to the tissue a therapeutically effective amount of a composition comprising an siRNA molecule that binds to an mRNA that codes for TGFB1 protein in a mammalian cell, an siRNA molecule that binds to an mRNA that codes for COX-2 protein in a mammalian cell, and a pharmaceutically acceptable carrier comprising a pharmaceutically acceptable histidine-lysine polymer. The invention also provides additional methods for using this composition.

Abstract: The present invention relates to compositions and methods for siRNA therapeutics for prevention and treatment of Middle East Respiratory Syndrome Corona Virus (MERS-CoV) infections. The compositions include a pharmaceutical composition comprising siRNA cocktails that target viral genes and pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers.

Abstract: High-specificity antibodies can distinguish between modified (e.g, hIGF-1/Ea 3mut) and endogenous wild-type human IGF-1 proteins. These antibodies have little or no cross-reactivity with hIGF-1 or hIGF-2. They also have little or no cross-reactivity with rodent IGF-1 or IGF-2. The antibodies can be used in pharmacokinetic (PK)/pharamcodynamic (PD) assessments of IGF-1/E peptides that have been administered to humans or animals. A sandwich ELISA assay, using the antibody of the invention as a capture antibody, can quantify the mutant IGF-1/E proteins in samples.

Abstract: High-specificity antibodies can distinguish between modified (e.g, hIGF-1/Ea 3mut) and endogenous wild-type human IGF-1 proteins. These antibodies have little or no cross-reactivity with hIGF-1 or hIGF-2. They also have little or no cross-reactivity with rodent IGF-1 or IGF-2. The antibodies can be used in pharmacokinetic (PK)/pharamcodynamic (PD) assessments of IGF-1/E peptides that have been administered to humans or animals. A sandwich ELISA assay, using the antibody of the invention as a capture antibody, can quantify the mutant IGF-1/E proteins in samples.

Abstract: High-specificity antibodies can distinguish between modified (e.g, hIGF-1/Ea 3mut) and endogenous wild-type human IGF-1 proteins. These antibodies have little or no cross-reactivity with hIGF-1 or hIGF-2. They also have little or no cross-reactivity with rodent IGF-1 or IGF-2. The antibodies can be used in pharmacokinetic (PK)/pharamcodynamic (PD) assessments of IGF-1/E peptides that have been administered to humans or animals. A sandwich ELISA assay, using the antibody of the invention as a capture antibody, can quantify the mutant IGF-1/E proteins in samples.

Abstract: The present disclosure provides transgenic seeds and plants with enhanced cold tolerance and cold vigor. The disclosure also provides methods of producing these transgenic plants and seeds. The present disclosure further provides methods of producing crops that can be grown under sub-optimum conditions and methods of increasing the yield of crop plants by extending growing season of a plant by earlier planting of transgenic seeds of the invention under sub-optimum growth conditions.